Smithfield Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Smithfield Trust’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7	Closed	-$1K	–	1003
2024 Q1	$1K	Buy	+7	New	+$2.3K	﹤0.01%	1035
2023 Q4	–	Sell	-5	Closed	-$2K	–	1008
2023 Q3	$2K	Hold	5	–	–	﹤0.01%	974
2023 Q2	$2K	Sell	5 -65	-93%	-$26.5K	﹤0.01%	988
2023 Q1	$33K	Hold	70	–	–	﹤0.01%	593
2022 Q4	$30K	Hold	70	–	–	﹤0.01%	583
2022 Q3	$29K	Hold	70	–	–	﹤0.01%	583
2022 Q2	$34K	Hold	70	–	–	﹤0.01%	590
2022 Q1	$40K	Hold	70	–	–	﹤0.01%	588
2021 Q4	$53K	Hold	70	–	–	﹤0.01%	553
2021 Q3	$53K	Hold	70	–	–	﹤0.01%	547
2021 Q2	$45K	Hold	70	–	–	﹤0.01%	567
2021 Q1	$40K	Hold	70	–	–	﹤0.01%	585
2020 Q4	$41K	Hold	70	–	–	﹤0.01%	556
2020 Q3	$37K	Buy	70 +5	+8%	+$2.53K	﹤0.01%	550
2020 Q2	$29K	Hold	65	–	–	﹤0.01%	566
2020 Q1	$23K	Buy	+65	New	+$23.9K	﹤0.01%	549

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Smithfield Trust's BIO Position: Q2 2024 in Review

Smithfield Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 7 shares — an estimated $1K sold.

Smithfield Trust first reported a position in BIO in Q1 2020 and held it in 16 quarters. The position peaked at $53K in Q4 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Smithfield Trust reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Smithfield Trust sold 7 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $1K.
Smithfield Trust first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 16 quarters.
Smithfield Trust's Bio-Rad Laboratories Class A position peaked at $53K in Q4 2021.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Smithfield Trust's 13F filing for Q2 2024, filed 31 Jul 2024.